Photoreaction potential of orally administered levofloxacin in healthy subjects.
OBJECTIVE
To evaluate the photoreaction potential of levofloxacin on exposure to solar-simulating radiation. Solar-simulating is ultraviolet (UV) light, defined as UVA in the 320-400 nm range and UVB in the 290-320 nm range.


METHODS
In a single-center, double-blind, randomized study, 30 adults (20 men, 10 women) received oral levofloxacin (500 mg qd x 5 d) or placebo. At baseline photoexposure prior to drug administration, each subject was exposed to UVB light at 0.75, 1.0, and 2.0 times the minimal erythema dose and to UVA light (25 J/cm2). Photoexposure was repeated on day 5, two hours following final drug administration, and response was determined using both a photoreaction rating scale and investigator assessment.


RESULTS
Using the photoreaction rating scale, following UVB exposure on day 5, no abnormal photoreactions were observed among levofloxacin recipients. UVA exposure was associated with mild reactions in 20 of 24 levofloxacin-treated and three of six placebo-treated subjects, with no associated symptoms. By investigator assessment, all subjects had a negative reaction to UVB photoexposure, and 10 of 24 levofloxacin-treated and three of six placebo-treated subjects had a photoreaction following UVA photoexposure. Dermal reactions were mild and similar for both treatment groups. No subject experienced an immediate wheal-and-flare reaction. There were no statistically significant differences between treatment groups for any of the comparisons.


CONCLUSIONS
Levofloxacin has a low photosensitizing potential when administered to healthy subjects.
Boccumini
L E
LE
The RW Johnson Pharmaceutical Research Institute, Raritan, NJ 08869, USA.
Fowler
C L
CL
Campbell
T A
TA
Puertolas
L F
LF
Kaidbey
K H
KH
D000284:Administration, Oral; D000293:Adolescent; D000328:Adult; D000890:Anti-Infective Agents / Q000009:adverse effects*; D017484:Dermatitis, Phototoxic / Q000209:etiology*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D064704:Levofloxacin; D008297:Male; D015242:Ofloxacin / Q000009:adverse effects*; D010777:Photochemistry; D014466:Ultraviolet Rays
D000890:Anti-Infective Agents; D064704:Levofloxacin; D015242:Ofloxacin